Literature DB >> 8573632

The binding of 5-fluorouracil to native and modified human serum albumin: UV, CD, and 1H and 19F NMR investigation.

C Bertucci1, G Ascoli, G Uccello-Barretta, L Di Bari, P Salvadori.   

Abstract

5-Fluorouracil (FU) is an important and widely used antineoplastic drug that is carried in the serum by plasma proteins. Protein binding studies of this drug to human serum albumin (HSA) have been carried out by several spectroscopic techniques. Difference circular dichroism and UV studies provided information on the class of binding sites involved in the interaction. In particular, displacement experiments showed that FU has at least one secondary binding site in the coumarin binding area, but does not interact with the benzodiazepine binding area. Binding was also investigated by difference 1H NMR and by measuring the increase in the 19F NMR signal of FU when bound to HSA. Finally, evidence was obtained that chemical acetylation of Lys199 results in a decreased apparent binding affinity constant (nK) for FU. Such a modification is induced under physiological conditions by aspirin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8573632     DOI: 10.1016/0731-7085(95)01548-y

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  4 in total

1.  Effect of heating temperature and time on pharmaceutical characteristics of albumin microspheres containing 5-fluorouracil.

Authors:  Rajesh R Dubey; Jolly R Parikh; Rajesh R Parikh
Journal:  AAPS PharmSciTech       Date:  2003       Impact factor: 3.246

2.  The binding characteristics of the interaction between 3-(2-cyanoethyl) cytosine and human serum albumin.

Authors:  Feng-Ling Cui; Guang-Quan Hui; Rui-Na Huo; Gui-Rong Qu
Journal:  Mol Biol Rep       Date:  2012-07-19       Impact factor: 2.316

3.  Lymph node effective vascular permeability and chemotherapy uptake.

Authors:  Eelco F J Meijer; Cedric Blatter; Ivy X Chen; Echoe Bouta; Dennis Jones; Ethel R Pereira; Keehoon Jung; Benjamin J Vakoc; James W Baish; Timothy P Padera
Journal:  Microcirculation       Date:  2017-08       Impact factor: 2.628

4.  Optimizing circadian drug infusion schedules towards personalized cancer chronotherapy.

Authors:  Roger J W Hill; Pasquale F Innominato; Francis Lévi; Annabelle Ballesta
Journal:  PLoS Comput Biol       Date:  2020-01-27       Impact factor: 4.475

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.